Cargando…

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

BACKGROUND: Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major pathway that can block cell proliferation or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tovar, Christian, Higgins, Brian, Kolinsky, Kenneth, Xia, Mingxuan, Packman, Kathryn, Heimbrook, David C, Vassilev, Lyubomir T
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094321/ https://www.ncbi.nlm.nih.gov/pubmed/21539745 http://dx.doi.org/10.1186/1476-4598-10-49

Ejemplares similares

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
por: Culig, Zoran
Publicado: (2021)

MDM2 Antagonists Counteract Drug-Induced DNA Damage
por: Vilgelm, Anna E., et al.
Publicado: (2017)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
por: Bronte, Vincenzo, et al.
Publicado: (2005)

Targeting the p53–MDM2 interaction to treat cancer
por: Klein, C, et al.
Publicado: (2004)

Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells
por: Terakawa, T, et al.
Publicado: (2009)

Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
por: Uy, Geoffrey L., et al.
Publicado: (2020)

Second generation androgen receptor antagonists and challenges in prostate cancer treatment
por: Chen, Yanhua, et al.
Publicado: (2022)

Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells
por: Chopra, Harman, et al.
Publicado: (2017)

MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()()
por: Feng, Felix Y., et al.
Publicado: (2016)

Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
por: Kokal, Miriam, et al.
Publicado: (2020)

Augmented antitumor activity of 5‐fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells
por: Imanishi, Mamiko, et al.
Publicado: (2019)

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
por: Gaughan, Luke, et al.
Publicado: (2005)

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer
por: Johnson, James K., et al.
Publicado: (2016)

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
por: Rajaram, Pravien, et al.
Publicado: (2020)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
por: Sugawara, Tatsuo, et al.
Publicado: (2019)

Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia
por: Yang, Minggen, et al.
Publicado: (2021)

Synthesis of Hydantoin Androgen Receptor Antagonists and Study on Their Antagonistic Activity
por: Ma, Longjun, et al.
Publicado: (2022)

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen
por: Qin, Jiang-Jiang, et al.
Publicado: (2017)

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
por: Smith, Matthew R., et al.
Publicado: (2016)

Boosting Anion Transport Activity of Diamidocarbazoles by Electron Withdrawing Substituents
por: Maslowska-Jarzyna, Krystyna, et al.
Publicado: (2021)

Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model
por: Miyake, H, et al.
Publicado: (2001)

Mouse models of Mdm2 and Mdm4 and their clinical implications
por: Xiong, Shunbin
Publicado: (2013)

Correction to ‘Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation’
por: Gaughan, Luke, et al.
Publicado: (2021)

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
por: Jungwirth, A., et al.
Publicado: (1997)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Antagonistic Functions of Androgen Receptor and NF-κB in Prostate Cancer—Experimental and Computational Analyses
por: Basílio, José, et al.
Publicado: (2022)

Cheminformatic Analysis and Machine Learning Modeling to Investigate Androgen Receptor Antagonists to Combat Prostate Cancer
por: Yu, Tianshi, et al.
Publicado: (2023)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
por: Wiley, Christopher D., et al.
Publicado: (2018)

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
por: Neochoritis, Constantinos G, et al.
Publicado: (2019)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists
por: Sriraman, Anusha, et al.
Publicado: (2018)

Systems Pharmacology Modeling of Prostate‐Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down‐Regulator
por: Mistry, HB, et al.
Publicado: (2016)

LTP Induction Boosts Glutamate Spillover by Driving Withdrawal of Perisynaptic Astroglia
por: Henneberger, Christian, et al.
Publicado: (2020)

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape
por: Nagel, Remco, et al.
Publicado: (2022)

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2017)

SUN-139 Luminescence-Based Drug Screen for Novel Androgen Receptor Antagonists for Prostate Cancer Therapy
por: Azur, Romie Angelo G, et al.
Publicado: (2020)

H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer
por: Baratchian, Mehdi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i3gvpg0akbun3nfo0egrsqcah2